bluebird bio Inc (NAS:BLUE)
$ 0.6078 0.0338 (5.89%) Market Cap: 117.15 Mil Enterprise Value: 240.30 Mil PE Ratio: 0 PB Ratio: 0.29 GF Score: 25/100

bluebird bio Inc Initiates Restructuring to Reduce Operating Expenses and Advance Near-term Opportunities to Bring Potentially Curative Gene Therapies to Patients in the US Investor Call Transcript

Apr 05, 2022 / 12:00PM GMT
Release Date Price: $5.03 (-3.82%)
Operator

Good morning, and thank you for standing by. Welcome to the bluebird bio conference call. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Courtney O'Leary, Investor Relations. Please go ahead.

Courtney O;Leary
bluebird bio, Inc. - IR Officer

' -

Good morning, everyone, and thank you for joining today's call to discuss this morning's restructuring announcement. The press release announcing these updates can be found on the Investor Relations section of our website.

Before we begin, let me review our safe harbor statement. Today's discussion contains statements that are forward-looking under the Private Securities Litigation Reform Act of 1995, including our statements regarding potential cost savings from our restructuring and the expected impacts on our operating expenses and cash runway.

Such statements are based on current expectations and assumptions that are subject to risks and uncertainties and involve a number of risk factors that could cause actual results to differ

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot